Zenas BioPharma, Inc. (ZBIO) NASDAQ
25.40
+0.9(+3.67%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
25.40
+0.9(+3.67%)
Currency In USD
Address
North Building
Waltham, MA 02451
United States of America (the)
Phone
(857) 271-2954
Website
Sector
Healthcare
Industry
Biotechnology
Employees
130
First IPO Date
September 13, 2024
| Name | Title | Pay | Year Born |
| Leon Oliver Moulder Jr. | Chief Executive Officer & Chairman of the Board | 686,554 | 1957 |
| Lisa von Moltke | Head of Research & Development and Chief Medical Officer. | 332,542 | 1959 |
| Orlando Oliveira | Chief Commercial Officer | 509,897 | 1976 |
| Joseph L. Farmer | Chief Operating Officer & President | 757,454 | 1972 |
| Jennifer A. Fox | Chief Business Officer & Chief Financial Officer | 856,021 | 1972 |
| Haley Laken | Chief Scientific Officer | 0 | N/A |
| Heinrich Schlieker | Chief Technical Officer | 0 | N/A |
| Jeffrey Held | Chief Legal Officer | 0 | 1969 |
| Caroline Chevalier | Chief Human Resources Officer | 0 | N/A |
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.